Page last updated: 2024-11-13
icogenin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
Icogenin: a cytotoxic steroidal saponin isolated from Dracaena draco; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Dracaena | genus | A plant genus of the family Asparagaceae. The common name of dragon's blood is also used for CROTON and Daemonorops (ARECACEAE).[MeSH] | Asparagaceae | A family of flowering subshrubs and shrubs in the class Magnoliopsida.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 44410621 |
| CHEMBL ID | 427949 |
| MeSH ID | M0481198 |
Synonyms (2)
| Synonym |
|---|
| CHEMBL427949 |
| icogenin |
Research Excerpts
Overview
Icogenin was found to be a cytotoxic compound IC(50) 2.6+/-0.9microM at 72h, with growth inhibition caused by the induction of apoptosis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Icogenin was found to be a cytotoxic compound IC(50) 2.6+/-0.9microM at 72h, with growth inhibition caused by the induction of apoptosis, as determined by microscopy of nuclear changes and the fragmentation of poly(ADP-ribose) polymerase-1." | ( Icogenin, a new cytotoxic steroidal saponin isolated from Dracaena draco. Bermejo, J; Estévez, F; Hernández, JC; León, F; Quintana, J, 2004) | 2.49 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (9)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID263842 | Cytotoxicity against human A431 cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis and antitumor activity of icogenin and its analogue. |
| AID263838 | Cytotoxicity against human PC3M cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis and antitumor activity of icogenin and its analogue. |
| AID263843 | Cytotoxicity against human BEL-7402 cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis and antitumor activity of icogenin and its analogue. |
| AID263840 | Cytotoxicity against human HCT8 cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis and antitumor activity of icogenin and its analogue. |
| AID648751 | Cytotoxicity against human HL60 cells | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Synthesis and antitumor activity of 5,6-dihydro-17-hydroxy icogenin analogs. |
| AID263841 | Cytotoxicity against human BGC823 cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis and antitumor activity of icogenin and its analogue. |
| AID263836 | Cytotoxicity against human KETR3 cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis and antitumor activity of icogenin and its analogue. |
| AID263839 | Cytotoxicity against human H460 cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis and antitumor activity of icogenin and its analogue. |
| AID263837 | Cytotoxicity against human PANC1 cells by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis and antitumor activity of icogenin and its analogue. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||